|1.||De Backer, Daniel: 2 articles (01/2009 - 01/2005)|
|2.||Pickard, R: 2 articles (01/2005 - 01/2003)|
|3.||Glazener, C M A: 2 articles (01/2005 - 01/2003)|
|4.||Alhasso, A: 2 articles (01/2005 - 01/2003)|
|5.||Verkindre, C: 2 articles (11/2004 - 02/2003)|
|6.||Radenne, F: 2 articles (11/2004 - 02/2003)|
|7.||Sosa, Z Y: 2 articles (09/2001 - 08/2000)|
|8.||Casais, M: 2 articles (09/2001 - 08/2000)|
|9.||Rastrilla, A M: 2 articles (09/2001 - 08/2000)|
|10.||Snoeren, Eelke M S: 1 article (04/2015)|
|1.||Asthma (Bronchial Asthma)
05/01/1980 - "Thus, inhalation of beta-adrenergic agents is as effective as subcutaneous administration in the treatment of acute asthma in childhood."
07/01/1995 - "Recently, the use of continuous administration of Beta-adrenergic agents has been found to be a safe and effective method of therapy for the pediatric patient experiencing severe asthma. "
05/01/1980 - "We examined the efficacy of several beta-adrenergic agents commonly used to treat asthma and evaluated the optimum route of administration. "
09/01/1990 - "A controlled double-blind trial was carried out to assess the effect of the early introduction of combined corticosteroid and beta-adrenergic drugs for the treatment of acute asthma in infants and toddlers. "
06/01/1983 - "Patients with a known diagnosis of asthma, who presented to the investigators in acute respiratory distress, without any previous adrenergic agents for six hours, were the subjects for this study. "
|2.||Septic Shock (Toxic Shock Syndrome)
08/01/2004 - "Septic shock that requires therapy with adrenergic agents is associated with high rates of mortality. "
08/01/1995 - "Systolic and diastolic dysfunction occur during human septic shock, and sensitivity to beta-adrenergic agents is reduced. "
03/01/1992 - "In this pilot study, murine monoclonal anti-TNF antibody (2 mg/kg) was administered to ten patients within 24 h of septic shock which persisted after initial resuscitation with intravenous fluids and adrenergic agents. "
10/01/1990 - "Although the effectiveness of adrenergic drug therapy continues to be controversial, adrenergic drugs have been used for the treatment of newborn endotoxic shock. "
10/01/1993 - "Neuropeptide Y (NPY), a sympathetic and platelet-derived vasoconstrictor, acts both directly and by potentiating adrenergic responsiveness and therefore may be beneficial in endotoxic shock, where suppressed vascular responsiveness to adrenergic agents is a key factor. "
|3.||Chronic Obstructive Pulmonary Disease (COPD)
10/21/1991 - "Recent studies have shown that anticholinergic therapy is more effective than the most potent beta-adrenergic agents for chronic obstructive pulmonary disease. "
01/01/2011 - "The availability of a new once daily bronchodilator, that maximize efficiency of beta-2 adrenergics may provide clinicians with more flexibility in treating COPD, and may increase adherence to treatments for patients."
10/21/1991 - "For chronic obstructive pulmonary disease, anticholinergic compounds offer greater bronchodilation than beta-adrenergic agents for most patients and are thus considered useful initial therapy in maintenance regimens."
04/01/1991 - "Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD."
01/01/1990 - "In chronic obstructive lung disease, the anticholinergic compounds offer greater bronchodilatation than adrenergic drugs for the majority of patients. "
03/01/2010 - "The concentration of free fatty acids (FFA), particularly palmitate, is increased in obesity and by the action of beta-adrenergics. "
06/01/1996 - "Serotonergic drugs and adrenergic agents are available in the treatment of obesity. "
11/01/1995 - "Currently available obesity drugs include centrally acting adrenergic agents and serotonin agonists. "
01/01/1998 - "Obesity and use of beta-adrenergic drugs, which is indicative of obstructive respiratory problems, were the most important risk factors suggesting that mechanical strain on the sternotomy and sternal instability may precede infection. "
01/01/2011 - "Lifestyle intervention is essentially useless in this syndrome, termed "hypothalamic obesity." Pharmacologic treatment is also difficult, consisting of adrenergics to mimic sympathetic activity, or suppression of insulin secretion with octreotide, or both. "
01/01/1987 - "For patients with chronic obstructive bronchitis and emphysema, combination therapy may also increase the bronchodilatation achievable with beta-adrenergic agents alone. "
05/01/1984 - "Ipratropium will probably find its major application in the long-term management of chronic bronchitis and emphysema, and in asthmatic patients who are poorly controlled by, or who experience troublesome side effects from, adrenergic agents."
01/01/1987 - "In bronchitis and emphysema a large number of studies suggest that anticholinergic agents not only are more potent than adrenergic agents but, when given in optimal dosage, achieve all of the available bronchodilatation in these patients. "
11/01/1987 - "Anticholinergic bronchodilators are of interest as alternatives to beta-adrenergic agents, particularly in patients with chronic bronchitis and emphysema, yet little is known of the effects of either class of agent on gas exchange in patients with this diagnosis. "
|1.||Antidepressive Agents (Antidepressants)
|2.||Histamine Antagonists (Antihistamines)
|2.||Lymph Node Excision (Lymph Node Dissection)
|3.||Fluid Therapy (Oral Rehydration Therapy)
|4.||Drug Therapy (Chemotherapy)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)